Drugs / [99mTc]Tc-TECANT1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT05871320 | Dec 2022 → Jun 2023 | neuroendocrine neoplasm | Jagiellonian University | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [99mTc]Tc-TECANT1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05871320 ↗ |
| Modality | Diagnostic / imaging agent | “[99mTc]Tc-TECANT1 appears to be a safe and widely utilizable radiopharmaceutical for the assessment of SSTR expression status in NENs.” PMID 41887731 ↗ Jun 2026 |